NAV
$32.10
AUM
$21.4M
Expense Ratio
-
Dividend Yield
0.00%
Beta
0.00
Currency
USD
| YTD | 1M | 3M | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|
| +3.23% | -0.77% | +5.04% | +11.96% | - | - |
| # | Symbol | Name | Weight |
|---|---|---|---|
| 1 | ROP.SW | Roche Holding AG Ordinary Shares new | 3.44% |
| 2 | NOVN.SW | Novartis AG Registered Shares | 3.15% |
| 3 | OR.PA | L'Oreal SA | 2.77% |
| 4 | SIE.DE | Siemens AG | 2.69% |
| 5 | 7203.T | Toyota Motor Corp | 2.63% |
| 6 | SHEL.L | Shell PLC | 2.46% |
| 7 | AZN.L | AstraZeneca PLC | 2.46% |
| 8 | 6501.T | Hitachi Ltd | 2.31% |
| 9 | SAN.PA | Sanofi SA | 2.24% |
| 10 | 6758.T | Sony Group Corp | 2.01% |
The fund will invest in equity securities of publicly listed non-U.S. companies that Sparkline Capital LP believes are attractive relative to its proprietary measure of “intangible-augmented intrinsic value.” Under normal circumstances, the fund invests at least 80% of its net assets in equity securities of publicly listed non-U.S. companies, including common stocks and depositary receipts evidencing ownership of common stocks, that satisfy the sub-adviser’s definition of value.
Inception Date: 2024-09-09